HistoSonics has landed its first major reimbursement win as Blue Cross Blue Shield of Michigan (BCBSM) approved coverage for its non-invasive liver tumor procedure using the Edison system.
This milestone allows eligible patients access starting Feb. 1, ahead of a broader rollout on July 1, 2025. The system uses focused ultrasound to mechanically destroy tumors without heat, toxicity, or surgery—an alternative for patients intolerant to standard treatments.
The move follows 12-month safety and efficacy data and comes amid acquisition rumors valuing HistoSonics at $2.5B.
Follow MEDWIRE.AI for MedTech reimbursement and M&A updates.
